Otros idiomas Aura Biosciences, Inc.

Acciones

AURA

US05153U1079

Tiempo real estimado Cboe BZX Otros sitios de cotización 20:32:21 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
7,965 ^USD	+2,51 %		+10,18 %	-10,21 %

15/04	Raj Parekh dimitirá como miembro del consejo de administración de Aura Biosciences, Inc. con efecto a partir del 20 de junio de 2024	CI
27/03	Las acciones de Aura Biosciences suben tras los resultados del cuarto trimestre	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	15/04
Aura Biosciences Shares Rise Following Q4 Results	27/03
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/03
Aura Biosciences to Participate in Upcoming Investor Conferences	26/02
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan for First-Line Treatment of Early-Stage Choroidal Melanoma	08/12
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	08/12
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07/12
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07/12
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	16/11
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing	09/11
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights	09/11
Aura Biosciences to Participate in Upcoming Investor Conferences	08/11
Aura Biosciences Announces Pricing of Public Offering of Common Stock	07/11
Aura Biosciences Announces Proposed Public Offering of Common Stock	06/11
Aura Biosciences, Inc. Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-Sar) in Early-Stage Choroidal Melanoma	06/11
Aura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-Sar	06/11
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma	06/11
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma	01/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Aura Biosciences, Inc.

Acciones

AURA

US05153U1079

Otros idiomas

Filtros